Literature DB >> 4031319

Skin testing with an aqueous extract of cotton bract.

E N Schachter, M G Buck, W W Merrill, P Askenase, T J Witek.   

Abstract

Airway challenge with cotton bract extract (CBE) causes reversible bronchospasm in most volunteers never before exposed to CBE or the textile industry. Lung function abnormalities develop slowly after inhalation with a maximum effect reached within 2 hours and lung function slowly improving thereafter. When CBE was injected intradermally in three naive subjects with negligible airway response to CBE, we observed an initial wheal-and-flare reaction within minutes followed by erythema and subsequent induration that persisted for 24 to 48 hours. Microscopic examination of skin biopsy specimens obtained during the course of these reactions revealed edema in the early phase followed by perivascular infiltration of a mixed cellular nature in the subsequent stages of the reaction. Degranulation of mast cells was noted throughout the course of the reaction. These findings indirectly suggest that a nonspecific inflammatory reaction initiated by mast cell-derived mediators and sustained by the presence of infiltrating cells may be responsible for some of the airway effects observed in byssinosis.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4031319     DOI: 10.1016/0091-6749(85)90731-6

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  3 in total

Review 1.  Byssinosis: a review.

Authors:  R McL Niven; C A Pickering
Journal:  Thorax       Date:  1996-06       Impact factor: 9.139

2.  Immunological findings and respiratory function in cotton textile workers.

Authors:  E Zuskin; B Kanceljak; E N Schachter; T J Witek; J Mustajbegovic; S Maayani; M G Buck; N Rienzi
Journal:  Int Arch Occup Environ Health       Date:  1992       Impact factor: 3.015

3.  Effect of Fluosol-DA/O2 on the antitumor activity and pulmonary toxicity of bleomycin.

Authors:  B A Teicher; J S Lazo; W W Merrill; A E Filderman; C M Rose
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.